FDA: Samsca may cause irreversible liver damage
(HealthDay)—Patients who take Samsca (tolvaptan) may be at elevated risk for significant liver injury, according to a Jan. 25 safety alert issued by the U.S. Food and Drug Administration.
Jan 26, 2013
0
0